2013 Report on Tuberculosis, Research Funding Trends, 2005-2012

7/27/2019 2013 Report on Tuberculosis, Research Funding Trends, 2005-2012

1/18


2/18

A DOUBLE BLOW: PRIVATE-SECTOR

FUNDING FOR TB RESEARCH DROPS

SHARPLY AMID SEVERE PUBLIC-SECTOR

BUDGET CUTS

As Threat of Drug-Resistance Grows, BigPharma Decreases Investments in TB

research by 22 Percent


3/18

- The first time funding has fallen since TAG began tracking

investments in 2005

- Total funding of US$627.4 million leaves a gap of US$1.39billion measured against the US$2 billion funding target

called for by the

- Funding dropped most in the pharmaceutical sector,

where investments fell by 22% compared to 2011

- Funding declines in TB R&D today will delay the

development, approval and introduction of new drugs,

diagnostics and vaccines to fight TB

- Funding for pediatric TB remains woefully inadequate at

less than 2% of overall spending on TB R&D


4/18

Total TB R&D Funding: 20052012

2005 2006 2007 2008 2010

$700,000,000

$525,000,000

$417,824,708

$357,426,170

$350,000,000

$175,000,000

$0

$491,476,917

$473,920,682

$630,446,462$619,209,536

2009 2012

$657,815,332

2011

$627,389,725


5/18

Annual Global Plan Research Funding Targets versus 2012 Investments

Basic

ScienceNew Diagnostics New Drugs New Vaccines Operational

Research

$800,000,000

$740,000,000

$600,000,000

$400,000,000

$380,000,000

$340,000,000

$200,000,000

$80,000,000

$0

$420,000,000

$129,623,072$42,429,160

$237,815,172$86,558,192 $77,128,668

Global Plan Annual Targets 2012 Investments


6/18

Public(Overall)

61%

Private18%

Development Agencies)

7%

Philanthropy20%

TB R&D Funding by Donor Sector: 2012

Total: $627,389,725

(International

1%

Multilaterals


7/18

Pharmaceutical companies spent 22 percent less

on TB R&D in 2012 than they did in 2011, said

TAGs executive director, Mark Harrington. BigPharma has always trailed far behind the public

sector in funding TB research, and now their

wavering support is placing greater pressure on

public institutions in the U.S. and Europe, which

are battling short-sighted budget cuts due to

sequestration and fiscal austerity.

-- Mark Harrington, Executive Director of

Treatment Action Group


8/18

Basic Science

$129,623,072 (21%)

Vaccines$86,558,192 (14%)

Operational Research$77,128,668 (12%)

TB R&D Investments by Research Category: 2012Total: $627,389,725

Drugs$237,815,172 (38%)

Diagnostics$42,429,160 (7%)

Infrastructure/Unspecified$53,835,462 (8%)


9/18

Summary of Changes in TB R&D Investment, 20052012

2005 $357,426,121

2006 $417,824,708 $60,398,587 16.9% $60,398,587 16.9%

2007 $473,920,682 $56,095,974 13.4% $116,494,561 32.6%

2008 $491,476,917 $17,556,235 3.7% $134,050,796 37.5%

2009 $619,209,536 $127,732,619 26.0% $261,783,415 73.2%

2010 $630,446,462 $11,236,926 1.8% $273,020,341 76.4%

2011 $657,815,332 $27,368,870 4.3% $300,389,211 84.0%

2012 $627,389,725 -$30,425,607 -4.6% $269,963,604 75.5%

Year

Total TB R&D

InvestmentChange over

Previous Year

Change

over 2005Change overPrevious Year

Change

over 2005


10/18


11/18

In 2012, the Zeroes campaign first called for

global action and a new attitude in the fight

against tuberculosis (TB)

Goal: achieve zero TB deaths, new infections,

and suffering and stigma.>600 individual + organizational sign-

ons

ZEROTBDeaths/Infections/Suffering

www.treatmentactiongroup.org/tb/advocacy/zero-declaration
mailto:http://www.treatmentactiongroup.org/tb/zeroes-campaignmailto:http://www.treatmentactiongroup.org/tb/zeroes-campaign


12/18Source: Dye C. et al Prospects for TB Elimination. Annual Review of Public Health 2013. 34:3.1-3.16

ZEROTBDeaths/Infections/Suffering

www.treatmentactiongroup.org/tb/advocacy/zero-declaration


13/18

CONTACT:

Mike Frick, Treatment Action Group;

Tel. 1 405 388 4490

[email protected]

Samuel Nuttall, Stop TB Partnership; Tel. 41 7947 55534

www.treatmentactiongroup.org /tbrd2013
mailto:[email protected]://www.treatmentactiongroup.org/http://www.treatmentactiongroup.org/mailto:[email protected]:[email protected]


14/18

Basic Science: $129,623,072

NIAID$61,339,187 (47%)

Other NIH ICs$10,926,027 (8%)

BMGF

$4,744,134 (4%)

EC$11,238,376 (9%)

Wellcome Trust$3,563,514 (3%)

BMBF$2,701,509 (2%)

Funders under 2%$18,254,491 (14%)

NHLBI$9,067,163 (7%)

MRC$7,788,670 (6%)


15/18

TB Diagnostics: $42,429,160

$1,043,468 (2%)

Other NIH ICs$1,068,920 (3%)

INSERM

NIAID

$14,501,183 (34%)

USAID

$2,851,973 (7%)

CDC

$2,536,798 (6%)

WHO$1,256,326 (3%)

Wellcome Trust

$1,385,218 (3%)

Funders under 2%

$3,956,852 (9%)

BMGF

$11,316,422 (27%)

DFID

$2,512,000 (6%)


16/18

TB Drugs: $237,815,172

DFID$8,321,000 (4%)

CDC

$9,161,421 (4%)

USAID$5,793,027 (3%)

Otsuka

$60,018,386 (25%)

Funders under 2%

$29,443,477 (12%)

Company X$22,634,099 (10%)

NIAID

$41,032,931 (17%)

EC

$5,509,608 (2%)

BMGF

$45,485,164 (19%)

AstraZeneca

$10,303,559 (4%)


17/18

TB Vaccines: $86,558,192

BMGF$37,753,518 (44%)

EC$7,734,463 (9%)

NIAID$12,234,889 (14%)

DGIS$5,244,198 (6%)

Emergent Biosolutions$4,157,360 (5%)

Company Z$5,178,920 (6%)

MRC$3,654,641 (4%)

Funders under 2%$10,600,203 (12%)


18/18

Funders under 2%

$8,378,870 (11%)

NIAID$14,452,688 (19%)

Other NIH ICs

12,982,935 (17%)

BMGF

$12,302,441 (16%)

PEPFAR

$6,606,609 (8%)

GFATM

$6,000,000 (8%)

CIDA$1,684,379 (2%)

Operational Research: $77,128,668

DFID

$4,500,171 (6%)

CDC

$4,561,413 (6%)

Korea (reported)

$2,077,302 (3%)

USAID

$1,751,116 (2%)

Wellcome Trust

$1,830,745 (2%)

Documents

2013 Report on Tuberculosis, Research Funding Trends, 2005-2012